Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Vitamin d and light therapy: a new One-Two punch against skin cancer?

NCT ID NCT07241585

First seen Nov 21, 2025 · Last updated Jun 23, 2026 · Updated 25 times

Summary

This study tests whether taking high-dose vitamin D for 6 days before photodynamic therapy (PDT) can improve the immune system's ability to fight nonmelanoma skin cancer. About 54 adults scheduled for Mohs surgery will be randomly assigned to vitamin D or placebo. Researchers will compare immune markers in the tumor tissue to see if the combination triggers a stronger immune response.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BASAL CELL CARCINOMA are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Case Comprehensive Cancer Center, Cleveland Clinic Foundation Taussig Cancer Institute

    RECRUITING

    Cleveland, Ohio, 44106, United States

    Contact

    Contact

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

Vitamin D (dietary supplement)

What this could lead to

If successful, this could point toward a way to boost the immune system's attack on skin cancer cells using vitamin D and light therapy.

What could go wrong

This is a very early, small study (54 people) looking at immune markers, not cure rates. It may not lead to any new treatment.

Conditions

The condition(s) this trial relates to.

basal cell carcinoma squamous cell carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.